04.19.21 How To Navigate Compliance With FDA s 21 CFR Part 11
CUE Biopharma CEO Dan Passeri, JD joins the
Business of Biotech to discuss the development of their Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares how the CUE-100 series of candidates in its pipeline are being developed to address a scourge of HPV-related head, neck, and other cancers. Listen now and subscribe so you never miss an episode.
Featured Editorial
By Kyle Neuman, SAFE Identity
21 CFR Part 11, the FDA s regulation on electronic records and electronic signatures, causes sleepless nights for many quality control experts and directors of regulatory compliance at CROs and pharma companies. How can you ensure compliance with this regulation?